STROBE Statement—Checklist of items that should be included in reports of *cross-sectional studies*

	Item No	Recommendation
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract
		Indicated. (Abstract: Background)
		(b) Provide in the abstract an informative and balanced summary of what was done and
		what was found
		Provided (Abstract: Methods & Results).
Introduction		
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported
		Provided (paragraphs 1-4).
Objectives	3	State specific objectives, including any prespecified hypotheses
		Provided (paragraph 4).
Methods		
Study design	4	Present key elements of study design early in the paper
		Provided (Study area section, first sentence).
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment,
		exposure, follow-up, and data collection
		All provided (Sections: Study area, Study population, Data collection).
Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of participants
		Provided (Section: Study population).
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable
		Provided (Section: Data analysis).
Data sources/	8*	For each variable of interest, give sources of data and details of methods of assessment
	O	(measurement). Describe comparability of assessment methods if there is more than one
measurement		group
		Provided (Section: Data collection & questionnaire).
Bias	9	Describe any efforts to address potential sources of bias
		Provided (Section: Data collection) Interviewed and questionnaire administration was done by research assistants who had received adequate training on the administration of
		the questionnaire and on the purpose of the study.
Study size	10	Explain how the study size was arrived at
		Provided (Section: Study population). Sample size calculation was provided
Quantitative	11	Explain how quantitative variables were handled in the analyses. If applicable, describe
variables		which groupings were chosen and why
		Provided (Section: Data analysis).
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding
	12	Provided (Section: Data analysis).
		(b) Describe any methods used to examine subgroups and interactions
		NA
		(c) Explain how missing data were addressed
		Provided (Section: Results). Incomplete data were excluded.
		(d) If applicable, describe analytical methods taking account of sampling strategy
		NA
		(e) Describe any sensitivity analyses
		NA
Dogulta		
Results	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially
Participants	15"	eligible, examined for eligibility, confirmed eligible, included in the study, completing

		follow-up, and analysed
		Considered first sub-section of Results.
		(b) Give reasons for non-participation at each stage
		Provided.
		(c) Consider use of a flow diagram
		<mark>NA</mark>
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and
		information on exposures and potential confounders
		Provided (Section: Results & Table 1)
		(b) Indicate number of participants with missing data for each variable of interest NA
Outcome data	15*	Report numbers of outcome events or summary measures
		Considered.
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and
		their precision (eg, 95% confidence interval). Make clear which confounders were
		adjusted for and why they were included
		Considered. Multivariate analysis description at end of data analysis section & Table 6
		(b) Report category boundaries when continuous variables were categorized NA
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a
		meaningful time period NA
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses NA
Discussion		
Key results	18	Summarise key results with reference to study objectives
		Considered.
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or
		imprecision. Discuss both direction and magnitude of any potential bias
		Considered, end of discussion
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations,
		multiplicity of analyses, results from similar studies, and other relevant evidence
		Considered.
Generalisability	21	Discuss the generalisability (external validity) of the study results
		Considered, end of discussion.
Other information		
Funding	22	Give the source of funding and the role of the funders for the present study and, if
		applicable, for the original study on which the present article is based NA

^{*}Give information separately for exposed and unexposed groups.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at http://www.plosmedicine.org/, Annals of Internal Medicine at http://www.annals.org/, and Epidemiology at http://www.epidem.com/). Information on the STROBE Initiative is available at www.strobe-statement.org.